APLLTD vs BALPHARMA: Stock Comparison

ALEMBIC PHARMA vs BAL PHARMAUpdated 4 Sept 26, 4:08 PM ISTNSE & company filings

ALEMBIC PHARMA is the larger company by market capitalisation. ALEMBIC PHARMA shows a higher ROE, a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

APLLTD leads 10; BALPHARMA leads 1 of 11

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

APLLTDBALPHARMA

Valuation lens

What price are you paying?

Market CapContext only
₹15,837 Cr
₹141 Cr
P/E RatioSame reading
23.35x
P/B RatioSame reading
2.85x
EPSAPLLTD has the higher reading
₹10.02
₹0.71
Book ValueContext only
₹288.41
₹51.66
Dividend YieldAPLLTD has the higher reading
1.49%
1.36%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
APLLTD is the larger company
₹15,837 Cr vs ₹141 Cr
EPS
APLLTD has higher earnings per share
₹10.02 vs ₹0.71
Dividend Yield
APLLTD has a higher dividend yield
1.49% vs 1.36%
Revenue Growth (TTM YoY)
APLLTD has faster revenue growth
4.4% vs 2.7%
EPS Growth (TTM YoY)
APLLTD has faster EPS growth
29.2% vs -33.5%
Qtr Sales Growth
BALPHARMA has stronger quarterly sales growth
0.21% vs -13.1%
Qtr Profit Growth
APLLTD has stronger quarterly profit growth
14.27% vs -2.01%
ROE
APLLTD has a higher ROE
11.4% vs 7.69%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricAPLLTDBALPHARMA
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricAPLLTDBALPHARMA
Live Price₹808.2₹87.73
Day Change0.57%0.02%
Volume1.74 L8,210
52-Week High₹998₹98.85
52-Week Low₹635.8₹60
Distance from 52W High-19.02%-11.25%

Valuation

MetricAPLLTDBALPHARMA
Market Cap₹15,837 Cr₹141 Cr
P/E Ratio23.35x
P/B Ratio2.85x
EPS₹10.02₹0.71
Book Value₹288.41₹51.66
Dividend Yield1.49%1.36%

Growth

MetricAPLLTDBALPHARMA
Revenue Growth (TTM YoY)4.4%2.7%
EPS Growth (TTM YoY)29.2%-33.5%
Qtr Sales Growth-13.1%0.21%
Qtr Profit Growth14.27%-2.01%

Profitability & Leverage

MetricAPLLTDBALPHARMA
ROE11.4%7.69%
ROCE10.99%9.5%
Net Margin8.98%2.02%
Operating Margin11.13%7.3%
Debt to Equity0.2x1.94x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricAPLLTDBALPHARMA
Promoter Holding69.36% 0.13 pp46.74%
FII Holding4.18% 0.07 pp0.15% 0.01 pp
DII Holding15.94% 0.24 pp0%
Public Holding10.01% 0.18 pp48.99% 0.02 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: ALEMBIC PHARMA and BAL PHARMA.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.